Intensity-Modulated Radiation Therapy (for New Mexico Only)

Coverage Summary

This New Mexico–specific UnitedHealthcare medical policy (Policy Number CS064NM.C, effective May 1, 2026) defines coverage and medical necessity criteria for Intensity‑Modulated Radiation Therapy (IMRT) in individuals 19 years of age and older (IMRT is covered without further review for those <19).

IMRT is an advanced, high‑precision external beam radiation technique that modulates beam intensity (including rotational VMAT delivery) to conform dose to the three‑dimensional tumor target while minimizing dose to adjacent normal organs at risk. The policy notes that image‑guided radiation therapy (IGRT) (orthogonal and/or volumetric imaging such as cone‑beam CT) is often used with IMRT to improve localization and delivery accuracy.

Selected thresholds / key facts

APBI — DCIS tumor size≤ 2.5 cm

APBI — general surgical margin (suitable)≥ 2 mm

APBI — DCIS surgical margin≥ 3 mm

APBI regimen (preferred per NCCN/ASTRO)IMRT/VMAT, five fractions (preferred schedule: five fractions every other day; Florence trial used 30 Gy in 5 fractions)

Hippocampal exclusion distanceNo metastases within 5 mm of the hippocampus

HA-WBRT expected survival thresholdPrognosis ≥ 4 months required for HA-WBRT plus memantine

WBRT memantine regimen30 Gy in 10 fractions (WBRT + memantine referenced)

IHC (intrahepatic cholangiocarcinoma) BED thresholdBED > 80.5 Gy associated with improved 3-year OS and local control

Medical-Necessity Criteria

Guidelines & Evidence Summary

The policy’s clinical evidence section summarizes guideline endorsements and randomized and observational trials showing that IMRT (including VMAT and IGRT where indicated) reduces dose to organs at risk and often lowers acute and late toxicity while maintaining similar tumor control compared with older 2D/3D techniques across many tumor sites.

Key guideline and trial highlights in the policy include: ASTRO, NCCN and other specialty society recommendations preferring IMRT/VMAT for many anatomic sites to reduce toxicity and preserve function; randomized evidence for hippocampal‑avoidance WBRT (HA‑WBRT) with memantine (NRG/CC001) showing preserved cognitive function without compromising intracranial control or survival; randomized and large trials (e.g., PARCER) demonstrating reduced GI toxicity with IG‑IMRT versus 3D‑CRT for postoperative pelvic radiation (cervical/endometrial); randomized breast APBI trials (Florence, others) supporting APBI‑IMRT regimens in selected early‑stage patients; and secondary analyses and meta‑analyses (e.g., RTOG 0617 analyses, esophageal and lung studies) reporting lower heart and lung doses and less high‑grade pneumonitis or other toxicities with IMRT while maintaining comparable survival or control.

Applicable Codes

Referenced CPT / Procedure Codes (for IMRT and related services)CPT

77301	Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications
77338	Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan
77387	Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed
77407	Radiation treatment delivery; Level 2, single-isocenter (e.g., 3D or IMRT), photons, including imaging guidance, when performed
77412	Radiation treatment delivery; Level 3, multiple isocenters with photon therapy or single-isocenter with active motion management, including imaging guidance, when performed
77520	Proton treatment delivery; simple, without compensation
77522	Proton treatment delivery; simple, with compensation
77523	Proton treatment delivery; intermediate
77525	Proton treatment delivery; complex

Added CPT codesCPT

77407	radiation treatment delivery, intermediate (standard single-isocenter IMRT or VMAT should be billed under 77407)
77412	radiation treatment delivery, complex (for multiple isocenters or single-isocenter with active motion-management; documentation must justify level 3 vs level 2)

Removed CPT/HCPCS codesmixed

77385
77386
G6015
G6016
G6017

Provider Actions & Documentation Requirements

Documentation Required

Medical record documentation required

Patient medical record must contain documentation that fully supports medical necessity, including relevant medical history, physical examination, and results of pertinent diagnostic tests or procedures. Documentation must be legible, maintained in the patient's medical record, and made available upon request.

Prior Authorization

Case-by-case exception evaluation

Requests for IMRT for indications not listed as proven will be evaluated on a case-by-case basis. An exception requires demonstration (for example, comparative IMRT vs non-IMRT treatment plans) when a non-IMRT technique would increase the probability of clinically meaningful normal tissue toxicity, or when prior irradiation requires sculpting dose distribution to avoid exceeding cumulative normal tissue tolerance.

Comparative treatment plans or other demonstration required for exception requests

Definitions

Definitive Therapy: Radiation treatments for cancer with curative intent (NCCN 2025; National Cancer Institute definition summarized).

IMRT: Intensity‑Modulated Radiation Therapy, including VMAT delivery; an advanced conformal external beam radiation technique that modulates beam intensity to conform dose to target while sparing adjacent organs at risk (OARs).

APBI: Accelerated Partial‑Breast Irradiation.

PMRT: Postmastectomy Radiation Therapy.

IGRT: Image‑Guided Radiation Therapy (orthogonal imaging and/or volumetric imaging such as cone‑beam CT) used to verify localization and improve delivery accuracy.

DIBH: Deep Inspiration Breath Hold (respiratory control technique to reduce heart/lung dose for left‑sided breast/chest wall targets).

HA‑WBRT: Hippocampal‑Avoidance Whole Brain Radiation Therapy — a WBRT technique that spares the hippocampus to preserve cognitive function.

DO‑IMRT: Dysphagia‑Optimized IMRT — IMRT planned to reduce dose to swallowing‑related structures.

BED / BED10: Biologically effective dose; BED10 denotes BED calculated with α/β = 10, used to compare fractionation schemes (e.g., IHC retrospective threshold BED > 80.5 Gy cited).

Note: The policy includes an updated, expanded definition of Definitive Therapy in the Definitions section of the policy document (policy text updated May 1, 2026).

Evidence & Guideline References

Study/Guideline	Key finding/Value
PARCER trial (Chopra et al. 2021)	IG-IMRT reduced 3‑year grade ≥2 late GI toxicity (78% toxicity‑free vs 57% for 3D‑CRT) and lower serious GI toxicity at 4 years (19% vs 38%) with similar pelvic control
PORTEC3 secondary analysis (Wortman et al. 2022)	IMRT associated with fewer grade ≥3 AEs and lower rates of diarrhea and hematologic AEs vs 3D‑CRT in high‑risk endometrial cancer
RTOG 0617 (NRG Oncology) secondary analyses	IMRT linked to lower heart doses and ~two‑fold reduction in grade ≥3 pneumonitis; similar OS/PFS to 3D‑CRT
HA‑WBRT trials / NRG CC001 (Brown et al. 2020; Gondi et al. 2023)	HA‑WBRT + memantine reduced cognitive failure (adjusted HR 0.74) and preserved memory vs WBRT; no OS or intracranial PFS detriment
ASTRO / guideline endorsements (multiple: ASTRO, NCCN, ACR, ESGO/ESTRO/ESP)	Guidelines recommend IMRT/VMAT to reduce toxicity and spare OARs across many tumor sites; IGRT encouraged/required in several settings
HCC meta‑analysis (Jang 2023) and ASTRO liver guideline	Pooled response rate 58%, 1‑yr local control 84%, median OS 13 months; ASTRO recommends EBRT/IMRT as an option and dose‑escalation/hypofractionation where appropriate
Esophageal studies (Lan et al. 2020; meta‑analysis Xu et al. 2017)	IMRT associated with improved OS, PFS and lower radiation pneumonitis in propensity‑matched study; meta‑analysis shows reduced lung/heart volumes and higher OS vs 3D‑CRT
DO‑IMRT RCT (Nutting et al. 2023)	Dysphagia‑optimized IMRT improved MDADI swallowing scores at 12 and 24 months vs standard IMRT with fewer serious AEs
Cervical cancer evidence (PARCER + meta‑analyses) and guidelines	Image‑guided IMRT reduced acute and late GI/GU toxicity vs 3D‑CRT with similar pelvic control; PARCER supports IG‑IMRT as new standard when resources allow
Intrahepatic cholangiocarcinoma / IHC dose‑response (Tao et al. 2016)	BED >80.5 Gy associated with improved 3‑yr OS (73% vs 38%) and local control (78% vs 45%); supports dose‑escalation with advanced techniques
Non‑small cell lung cancer (RTOG 0617 secondary analyses; Chun et al. 2024)	IMRT reduced heart V40 and severe pneumonitis, with similar survival; heart dose associated with OS
Small cell lung cancer (Yang et al. 2023) and ARS/ASTRO guidance	Dose‑escalated IMRT (BED10 >70 Gy) linked to improved 1‑ and 3‑yr OS and local control without increased pneumonitis; guidelines endorse highly conformal techniques
Rectal cancer (RAPIDO trial; meta‑analysis Wee 2018)	RAPIDO: short‑course RT + chemo reduced 3‑yr disease‑related treatment failure; meta‑analysis: IMRT reduced grade ≥2 acute GI toxicity vs 3D‑CRT (OR 0.38 for overall GI)
Pancreatic cancer evidence and ASTRO guideline	IMRT associated with reduced acute GI toxicity vs 3D‑CRT and is recommended for localized pancreatic cancer planning/delivery
Prostate cancer outcomes (Abu‑Gheida 2019; Viani 2016)	Long‑term biochemical relapse‑free survival favorable across risk groups; RCT shows significantly less acute and late GU/GI toxicity with IMRT vs 3D‑CRT
Soft tissue sarcoma (Wang 2019) and ASTRO guidance	Postoperative IMRT associated with improved 5‑yr local recurrence‑free survival, DFS, DMFS, OS and reduced certain late toxicities vs 2D RT; IMRT recommended for retroperitoneal sarcoma
Vulvar cancer retrospective series (Richman, Rishi) and ESGO/NCCN statements	Dose‑escalated IMRT achieved high response rates with acceptable toxicity; adjuvant IMRT recommended with daily verification
Hodgkin lymphoma / mediastinal lymphoma systematic reviews and ILROG guidance	IMRT/VMAT can reduce high‑dose exposure to heart/esophagus and improve conformity; may increase low‑dose exposure requiring careful planning
APBI and breast RCTs (Florence APBI‑IMRT, NSABP B‑39/RTOG 0413, RAPID, ASTRO APBI)	Florence: APBI‑IMRT (30 Gy/5 fractions) had low 10‑yr IBTR and less toxicity; NSABP B‑39: APBI did not meet equivalence to WBI but small absolute differences; ASTRO recommends IMRT for APBI (5 fractions) in suitable patients
HA‑WBRT systematic review/meta‑analysis (Surendran 2025) and NRG CC001 final results	HA‑WBRT preserves delayed recall and reduces cognitive decline vs standard WBRT; trials report hippocampal dose sparing and functional benefit with memantine
PARSPORT / head & neck IMRT trials (Nutting 2011, GORTEC/TOGA etc.)	IMRT reduces xerostomia and late salivary toxicity vs conventional RT without compromising locoregional control or OS
Anal cancer trials and guidelines (RTOG 0529, Manfrida, ASTRO/ESMO/NCCN)	DP‑IMRT reduced acute hematologic and GI toxicity vs CRT; retrospective/observational studies show improved QOL and survival with IMRT
Hepatocellular carcinoma RCT (Wei 2023) and meta‑analysis	Neoadjuvant IMRT feasible with favorable response and manageable toxicity; pooled data show comparable survival and low severe liver toxicity
Endometrial cancer (PORTEC‑3 secondary analysis; Klopp et al. 2018)	IMRT associated with fewer severe/moderate side effects vs 3D‑CRT and better patient‑reported bowel/urinary outcomes; recommended as standard for adjuvant RT in high‑risk disease
CNS glioma guidelines and cohorts (ASTRO, Mills 2024)	Guidelines recommend IMRT/VMAT to reduce acute/late toxicity in grade 2–4 diffuse gliomas; cohort data show long PFS/OS with low late high‑grade toxicity
Intrahepatic cholangiocarcinoma evidence (Tao 2016) and ASTRO IHC guidance	BED >80.5 Gy associated with markedly better 3‑yr OS and local control in unresectable IHC; ASTRO conditionally recommends IMRT for dose‑escalated EBRT
Guideline endorsements summary (NCCN, ASTRO, ACR, ILROG, ASTRO/ASCO/SSO PMRT)	Multiple specialty guidelines prefer or recommend IMRT/VMAT and IGRT across tumor sites to minimize toxicity while preserving tumor control

Revision History

2026-05-01revisedLatest

Revised list of conditions for which IMRT for Definitive Therapy for the primary site is proven and medically necessary, including additions and wording changes for breast cancer criteria and head/neck and mediastinal listings. Detail: Replaced phrasing for breast cancer criteria; added hepatocellular carcinoma unresectable, Hodgkin lymphoma, intrahepatic cholangiocarcinoma unresectable, rectal cancer with inguinal nodes, limited-stage small cell lung cancer, retroperitoneal/intra-abdominal soft tissue sarcoma, and Stage I-II NSCLC undergoing hypofractionated RT up to 10 fractions; revised head and neck treatment area listings and mediastinal examples (added thyroid).

2026-05-01removedLatest

Removed language indicating compensator-based beam modulation is proven and medically necessary when combined with an IMRT indication.